Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at NYU Langone Health's Perlmutter Cancer Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

The initial findings of CheckMate-040 show that nivolumab was well tolerated and safe. The toxicity profile is better than what is seen currently with other agents, explains Welling. There have been significant responses seen with all subsets of patients.

There have been durable responses, states Welling. The data are still being analyzed to determine what the overall survival will be with the cohorts. Ongoing studies are being conducted to compare nivolumab with other agents.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Immuno-Oncology

Gastrointestinal Cancer

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Theodore H. Welling, MD, associate professor of surgery, director of the Liver Tumor Program at Perlmutter Cancer Center of NYU Langone Medical Center, discusses the efficacy of nivolumab (Opdivo) for patients with hepatocellular carcinoma (HCC).

Dr. Welling on the Efficacy of Nivolumab in HCC